tiprankstipranks
Advertisement
Advertisement

ATYR Stock Latest News

aTyr Pharma upgraded to Buy from Hold at Freedom Broker
The FlyaTyr Pharma upgraded to Buy from Hold at Freedom Broker
10d ago
ATYR
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 30.5% move in share price post-earnings
15d ago
ATYR
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
PremiumThe Fly
Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
15d ago
BX
DLO
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
PremiumThe Fly
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
15d ago
ATYR
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
PremiumRatings
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
18d ago
ATYR
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
PremiumRatingsJoseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
18d ago
ATYR
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
Premium
The Fly
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
19d ago
ATYR
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
Premium
Company Announcements
aTyr Pharma Announces New Phase 3 Sarcoidosis Trial
19d ago
8K
ATYR
ATYR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ATYR Upcoming Earnings Report: What to Expect?
19d ago
ATYR
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 14.1% move in share price post-earnings
22d ago
ATYR
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
PremiumCompany Announcements
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation
3M ago
ATYR
aTyr Pharma reports Q4 EPS (14c), consensus (17c)
PremiumThe Fly
aTyr Pharma reports Q4 EPS (14c), consensus (17c)
3M ago
ATYR
aTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
PremiumThe FlyaTyr Pharma announces U.S. FDA accepted meeting request for efzofitimod
4M ago
ATYR
aTyr Pharma Receives Nasdaq Deficiency Notice
Premium
Company Announcements
aTyr Pharma Receives Nasdaq Deficiency Notice
6M ago
8K
ATYR
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
Premium
Market News
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns
6M ago
ATYR
aTyr Pharma Reports Increased Losses Amid Rising R&D Costs
PremiumCompany Announcements
aTyr Pharma Reports Increased Losses Amid Rising R&D Costs
7M ago
ATYR
aTyr Pharma reports Q3 EPS (26c), consensus (18c)
PremiumThe Fly
aTyr Pharma reports Q3 EPS (26c), consensus (18c)
7M ago
ATYR
aTyr Pharma Inc options imply 21.3% move in share price post-earnings
PremiumThe Fly
aTyr Pharma Inc options imply 21.3% move in share price post-earnings
7M ago
ATYR
ATYR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ATYR Earnings this Week: How Will it Perform?
7M ago
ATYR
Atyr Pharma’s Promising Study on Efzofitimod for SSc-ILD: Key Insights for Investors
PremiumCompany AnnouncementsAtyr Pharma’s Promising Study on Efzofitimod for SSc-ILD: Key Insights for Investors
7M ago
ATYR
Symbotic, Serve Robotics, AeroVironment, aTyr Pharma, Cummins: Insider Moves Unveiled
Premium
Weekend Updates
Symbotic, Serve Robotics, AeroVironment, aTyr Pharma, Cummins: Insider Moves Unveiled
8M ago
CMI
SYM
aTyr Pharma Faces Legal Storm After Trial Failure
Premium
Class Action
aTyr Pharma Faces Legal Storm After Trial Failure
8M ago
ATYR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >